Immuneering (IMRX) announced a clinical supply agreement with Regeneron Pharmaceuticals (REGN) for its anti-PD-1 therapy, Libtayo. The supply ...
Hello, and welcome to Regeneron Pharmaceuticals' fourth quarter 2024 earnings conference call. My name is Tawanda, and I will be your operator for today's call. (Operator Instructions) Please note ...
Hosted on MSN20d
Pharma giant Regeneron is spending $119.5M on the world’s largest, most diverse genetic database using DNA from patient volunteersTruveta, a health data startup launched in 2020, announced the massive undertaking Jan. 13 along with biotech firm Illumina and the Regeneron Genetics ... such as the UK Biobank, which includes ...
Regeneron and GlaxoSmithKline have joined forces to generate genetic sequence data from the 500,000 volunteers in the UK’s Biobank database. The companies hope the initiative will give insights ...
Leerink upgraded Regeneron (REGN) to Outperform from Market Perform with a price target of $834, up from $762. The shares have fallen 35% over ...
Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...
Regeneron’s gene therapy for a profound form ... at Cambridge University Hospitals NHS Foundation Trust in the UK. “With these very preliminary DB-OTO results, we now have encouraging evidence ...
Regeneron’s total addressable commercial market is expected to exceed $220 billion by 2030. Some near-term highlights include: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback